<DOC>
	<DOCNO>NCT00700817</DOCNO>
	<brief_summary>This trial conduct Europe North America . The aim trial compare effect blood sugar control liraglutide sitagliptin , combination metformin , subject type 2 diabetes inadequately control metformin alone . The trial extend 52 week . The extension consist two 26-week period : 1 . Week 27-52 randomisation - All subject continue receive sitagliptin liraglutide unchanged dose dose regimen . 2 . Week 53-78 randomisation - Subjects receive sitagliptin end week 52 randomisation discontinue sitagliptin randomise 1:1 liraglutide 1.2 mg/day liraglutide 1.8 mg/day . Liraglutide initiate dose 0.6 mg/day , increase 1.2 mg/day 1.8 mg/day weekly interval . - Subjects receive liraglutide 1.2 mg/day 1.8 mg/day end week 52 randomisation continue treatment unchanged dose dose regimen . Trial completion plan June 2010 .</brief_summary>
	<brief_title>The Effect Liraglutide Compared Sitagliptin , Both Combination With Metformin Glycaemic Control Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes Treatment metformin alone least three month HbA1c ( glycosylated haemoglobin A1c ) 7.510.0 % ( inclusive ) Body Mass Index ( BMI ) less equal 45.0 Previous treatment insulin , glucagon like peptide1 ( GLP1 ) receptor agonist dipeptidyl peptidase4 ( DPP4 ) inhibitor Treatment antidiabetic drug metformin within last three month Any serious medical condition Females pregnant , intention become pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>